Characteristics, Trends of HCC in Patients Without Cirrhosis Characteristics, Trends of HCC in Patients Without Cirrhosis

This study aimed to describe the frequency and characteristics of non-cirrhotic hepatocellular carcinoma. What contribution does NAFLD make to the burden of non-cirrhotic HCC?Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Related Links:

This study aims to investigate the effect of periodontal treatment for liver damage,P. gingivalis infection, and endotoxemia on patients with NAFLD.MethodsWe will include adult patients (20 –85 years old) with NAFLD, alanine aminotransferase (ALT) ≥ 40 IU/L, and equivalent steatosis grade ≥ 1 (target sample size,n = 40 patients; planned number of patients with outcome data,n = 32). Participants will be randomly assigned to one of two groups: a scaling and root-planing group or tooth-brushing as the usual group. The primary outcome will be the change...
Source: Trials - Category: Research Source Type: clinical trials
Abstract Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease and associated with a wide spectrum of hepatic disorders ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). NASH is projected to become the most common indication for liver transplantation, and the annual incidence rate of NASH-related HCC is 5.29 cases per 1000 person-years. Owing to the epidemics of NAFLD and the unclear mechanism of NAFLD progression, it is important to elucidate the underlying NAFLD mechanisms in detail. NASH is mainly caused by t...
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease affecting approximately 25% of the global population. There is a collinearity between the severity of NAFLD and the components of the metabolic syndrome. NAFLD is also independently associated with cardiovascular disease and type 2 diabetes mellitus (T2DM). The progressive potential of non-alcoholic fatty liver disease (NAFLD) is today indisputable, and the histological spectrum of NAFLD ranges from isolated steatosis to non-alcoholic steatohepatitis (NASH), with risk of developing fibrosis and subsequent cirrhosis...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
AbstractThe growing burden of non-alcoholic fatty liver disease (NAFLD) parallels the increasing prevalence of obesity in Asia. The overall prevalence of NAFLD in Asia is now estimated to be 29.6% and may have surpassed that in Western populations. NAFLD increases with increasing age and is closely associated with metabolic syndrome. Ethnic differences exist in the prevalence of NAFLD, but the underlying factors are unclear. There were initial concerns about lean NAFLD being associated with more severe liver disease and increased mortality, but subsequent studies suggested otherwise. Only some NAFLD patients progress to de...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Basel, 4 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys ® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC). Dr. Amit Singal, Medical Director of the Liver Tumor Program   and Clinical Chief of Pathology at UT Southwestern Medical Center in Dallas, USA, stated, " HCC is the fourth leading cause of cancer-related death worldwide, wit...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Abstract Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease worldwide. This is primarily driven by the global epidemic of obesity and diabetes as well as the ageing of the general population. Most of the data regarding the epidemiology of NAFLD is published from the studies originating in the U.S. The overall prevalence of NAFLD in the United States is estimated to be 24%. In the U.S., Hispanic Americans have a higher prevalence of NAFLD, whereas African Americans have lower prevalence of NAFLD. The exact contributions of genetic and environmental factors on...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder of hepatic lipid metabolism that leads to steatosis, and can progress to cirrhosis and hepatocellular carcinoma, usually in conjunction with over-nutrition and the metabolic syndrome.1 A central molecular driver of progression is lipotoxicity, a process involving multiple lipid species and pathways that result in hepatocyte damage, liver inflammation and fibrogenesis.2
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research
In this study, we evaluated the diagnostic value of serum Golgi protein 73 (GP73) for hepatic necroinflammatory damage in patients with NASH. Methods: The clinical data of 201 patients with NASH diagnosed by liver biopsy according to the Brunt staging system were collected retrospectively. The in situ expression of GP73 protein was measured by immunohistochemistry. The receiver operating characteristic (ROC) curve was used to calculate the area under the ROC curve (AUROC) of serum GP73 for diagnosing hepatic necroinflammatory damage. Results: The serum GP73 levels of NASH patients increased with the aggravation of ...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Authors: Canup BSB, Song H, Laroui H Abstract CD98 is a multifunctional glycoprotein that is involved in various biological processes such as amino acid transport, cell adhesion, diffusion, adhesion, and proliferation. The role of CD98 in liver disease has not thoroughly been examined and is limited reports in the literature. Among these reports, direct association for CD98 in nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) have been reported. Our lab has reported that targeting CD98 in high fat diet mice reduced steatosis and inflammation in NAFLD. Other reports associate CD98 in HCC du...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Lifestyle modifications focused on healthy eating and regular exercise are the primary recommendations for patients with NASH. However, for multiple societal, psychological, physical, genetic, and epigenetic reasons, the ability of people to adopt and sustain such changes is challenging and typically not successful. To end the epidemic of NASH and prevent its complications including cirrhosis and hepatocellular carcinoma, pharmacological interventions are now being evaluated in clinical trials. Treatments include drugs targeting energy intake, energy disposal, lipotoxic liver injury, and the resulting inflammation and fibr...
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Drugs & Pharmacology | Gastroenterology | Health | Hepatocellular Carcinoma | Liver Cancer | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study